Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is beneficial compared to placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Atorvastatin; Atorvastatin Calcium; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Hospital admission for ACS with chest pain or discomfort occurring during rest or with minimal exertion,

• Percutaneous coronary intervention (PCI) planned,

• Evidence of coronary artery disease

Exclusion Criteria:

• Hypersensitivity to statins

• Any cholesterol lowering medication taken within 1 month prior V1

• Sustained ST-segment elevation on ECG